GAIN-1 Study: Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma

Trial Profile

GAIN-1 Study: Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 May 2017

At a glance

  • Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms GAIN-1
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Jun 2015 Tumour SPARK expression in GAIN-1 patients versus matched controls not receiving neoadjuvant therapy presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 28 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top